3 results
Approved WMORecruiting
Safety and efficacy objectives:The objective is to compare the safety and efficacy of masitinib at 6 of 7.5 mg/kg/day to imatinib at 400 or 600 mg, in patients with gastro-intestinal stromal tumour in first line medical treatment.
Approved WMORecruiting
The objective is to compare the efficacy and safety of masitinib 12 mg/kg/day to sinutinib 50 mg/day
Approved WMORecruiting
Investigate the effect of hilotherapy on the severity of CIPN and nail toxicity, and its influence on treatment management and quality of life in patients with breast cancer during, and three and six months after treatment with Paclitaxel.